When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
QLGN - Qualigen contracts TD2 for preclinical development of QN-302
Qualigen Therapeutics Inc.
Qualigen Therapeutics (NASDAQ:QLGN +3.5%) selected contract research organization (CRO) Translational Drug Development (TD2) to lead the preclinical development of its lead drug candidate QN-302. Qualigen is initially investigating QN-302 for the potential treatment of pancreatic ductal adenocarcinoma (PDAC), a type of pancreatic cancer.